Asset Details
Do you wish to reserve the book?
Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk
Do you wish to request the book?
Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk
2023
Overview
The study compared the incidence of cancer between patients with diabetes with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors use.
This study identified a non-SGLT2 inhibitor cohort of 325,989 patients and a SGLT2 inhibitor cohort of 325,990 patients. The primary interest of this study was the occurrence of cancer. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models.
Patients receiving SGLT2 inhibitors (adjusted HR = 0.79, 95 % CI = 0.76–0.83) had a significantly lower risk of developing cancer than patients without receiving SGLT2 inhibitors.
The results demonstrated that patients with diabetes receiving SGLT2 inhibitors had a significantly lower risk of cancer.
•The study compared the incidence of cancer between patients with diabetes with and without SGLT2 inhibitors use in Taiwan between 2016-2019.•The strength of this study was from a large dataset.•Out study showed that patients with diabetes who took SGLT2 inhibitors had a significantly lower risk of cancer.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Cancer
/ Chronic obstructive pulmonary disease
/ Diabetes
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - epidemiology
/ Glucose
/ Humans
/ Insulin
/ Lipids
/ Neoplasms - chemically induced
/ Patients
/ Risk
/ Sodium
/ Sodium-glucose cotransporter-2 inhibitors
